Frontiers in Cardiovascular Medicine

MARCH 9, 2025

Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR. Clinical valve thrombosis is rare.

Aortic valve 52

Aortic valve Aortic TAVR Thrombosis 52

Heart BMJ

JANUARY 29, 2025

Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aortic valve replacement (TAVR). Methods This prospective cohort study consecutively enrolled patients with severe symptomatic aortic stenosis who underwent successful TAVR. Trial registration number ChiCTR2300072300.

Aortic valve 52

Aortic valve Thrombosis Aortic Technology 52

DAIC

MAY 15, 2024

Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the heart— transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR). 1.11, p=0.70) with similar long-term mortality risks.

Aortic valve 105

Aortic valve TAVR Outcomes Aortic 105

Cardiology Update

APRIL 9, 2024

SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve. vs. 6.2%) and stroke (2.9% vs. 4.7%) compared to SAVR.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52